Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 5/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | PER2 | O15055 | 8/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13623048 | 0.80 | PIK3CD (0.52) | PIK3CDPOLBPER2NPC1RAB9A | |
| SCHEMBL14275822 | 0.79 | TLR4 (0.31) | NPC1RAB9A | |
| SCHEMBL374144 | 0.76 | POLB (0.33) | POLBNPC1RAB9A | |
| SCHEMBL974356 | 0.76 | POLB (0.33) | POLBNPC1RAB9A | |
| SCHEMBL4760430 | 0.73 | BRD4 (0.33) | NPC1RAB9A | |
| SCHEMBL4760434 | 0.72 | KMT2A (0.38) | NPC1RAB9A | |
| SCHEMBL13647210 | 0.72 | MAPT (0.43) | POLBDPP4 | |
| SCHEMBL31291767 | 0.71 | PER2 (0.32) | PER2 | |
| Hydrochloric Acid SCHEMBL4339603 | 0.71 | BRD4 (0.33) | NPC1RAB9A | |
| SCHEMBL13622593 | 0.71 | SRD5A1 (0.59) | PIK3CDPOLBPER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212155-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230212155-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20210053946-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2021-02-25 | — | — | US | disclosed |
| US-10710986-B2 | PD-1/PD-L1 inhibitors | GILEAD SCIENCES, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-20190270727-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. | 2019-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212155-A1 | PD-1/PD-L1 INHIBITORS | PDCD1, CD274, PDCD1LG2 | PIK3CD 3024/4885POLB 382/4885PER2 4088/4885 |
| US-20210053946-A1 | PD-1/PD-L1 INHIBITORS | PDCD1, CD274, PDCD1LG2 | PIK3CD 3024/4885POLB 382/4885PER2 4088/4885 |
| US-10710986-B2 | PD-1/PD-L1 inhibitors | PDCD1, CD274, PDCD1LG2 | PIK3CD 3024/4885POLB 382/4885PER2 4088/4885 |
| US-20190270727-A1 | PD-1/PD-L1 INHIBITORS | PDCD1, CD274, PDCD1LG2 | PIK3CD 3024/4885POLB 382/4885PER2 4088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.